- Home
- LE vs OCGN Comparison
LE vs OCGN Comparison
Compare LE & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LE | OCGN |
|---|---|---|
| Founded | 1963 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.7M | 387.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LE | OCGN |
|---|---|---|
| Price | $14.46 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | $7.00 |
| AVG Volume (30 Days) | 205.3K | ★ 3.7M |
| Earning Date | 12-09-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,314,437,000.00 | $5,370,000.00 |
| Revenue This Year | $2.06 | $35.93 |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $38.68 | ★ N/A |
| Revenue Growth | N/A | ★ 14.26 |
| 52 Week Low | $7.65 | $0.52 |
| 52 Week High | $17.12 | $1.90 |
Technical Indicators
Market Signals| Indicator | LE | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 54.79 |
| Support Level | $14.00 | $1.37 |
| Resistance Level | $15.75 | $1.52 |
| Average True Range (ATR) | 0.75 | 0.10 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 30.65 | 57.50 |
Price Performance
Historical ComparisonAbout LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").